Latest From Mertiva AB
InDex Pharmaceuticals has named Peter Zerhouni its new CEO. Mr Zerhouni joins the company, which is developing lead product Kappaproct as a treatment of severe ulcerative colitis, from Diamyd Medical where he was also CEO. He succeeds Jesper Wiklund, who led the company since 2011.
Derived from Strategic Transactions, EBI’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals– and then categorized by type –Acquisition, Alliance, or Financing.
A New Collaborative Model? Janssen Joins Evotec And Harvard To Advance Regenerative Diabetes Projects
Germany's drug discovery services company Evotec has formed a tight bond with Harvard researchers, with both parties expected to share the rewards of their CureBeta pancreatic beta-cell regeneration project if new strategic partner Janssen Pharmaceuticals develops new diabetes therapies from their research.
Sweden's BioInvent forges links with researchers at Queen Mary, University of London, and Cancer Research Technology, the commercial arm of charity Cancer Research UK, to identify new therapeutic antibodies for oncology.
- Gene Therapy, Cell Therapy
- Large Molecule
- Therapeutic Areas
- Metabolic Disorders
- Diamyd Medical AB
- Western Europe
- Parent & Subsidiaries
- Mertiva AB
- Senior Management
Andreas Bergsten, CEO
Anna Styrud, CFO
Erika Hillborg, Sr. Dir., Clin. Dev.
- Contact Info
Phone: (46) 8 661 00 26
Stockholm, SE-115 26
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.